Peanut Allergy Treatment Market Set for Significant Growth by 2031, Driven by Emerging Targeted Therapies and Rising Disease Awareness

Peanut Allergy Treatment Market Overview:

The global Peanut Allergy Treatment Market is projected to grow at a CAGR of around 12% over the next five years. Rising prevalence of peanut allergies worldwide, increasing rates of clinical diagnosis, growing acceptance of immunotherapy-based interventions, favorable regulatory approvals for standardized therapies, and heightened awareness among caregivers and healthcare professionals are major factors supporting market expansion. In addition, the increasing focus on pediatric allergy management and advancements in biologic therapies are further accelerating demand for effective peanut allergy treatment solutions.

Download Sample PDF Copy: https://meditechinsights.com/peanut-allergy-treatment-market/request-sample/

The peanut allergy treatment market comprises therapies and management approaches aimed at preventing, controlling, or reducing allergic reactions caused by peanut exposure. The market includes oral immunotherapy (OIT), biologic therapies targeting immune pathways, emergency epinephrine treatments, and several investigational approaches designed to improve immune tolerance. It also encompasses diagnostic support systems and patient monitoring protocols that assist in controlled desensitization and minimize the risk of severe allergic responses. Although treatment demand is predominantly driven by pediatric patients, the market is witnessing growing interest in adult-focused therapies as peanut allergy frequently continues into adulthood.

Increasing prevalence of peanut allergy among children driving market demand

The growing incidence of peanut allergies in children remains one of the strongest drivers of the peanut allergy treatment market. Research studies have consistently shown a steady increase in food allergies globally over the past two decades, with peanut allergy recognized as one of the most severe and persistent allergic conditions affecting children and adolescents. According to studies published by the NIH, peanut allergies are especially common in Western countries due to a combination of genetic predisposition, environmental influences, and infant dietary exposure patterns.

Unlike several food allergies that may diminish with age, peanut allergies often persist throughout life, creating sustained demand for long-term disease management solutions. This has increased reliance on FDA-approved immunotherapies, desensitization programs, and emergency preparedness treatments. As awareness rises, allergists and pediatricians are emphasizing early diagnosis and structured treatment plans, contributing to higher treatment adoption rates.

Educational institutions and public facilities have also strengthened allergy management practices through nut-free policies and anaphylaxis response protocols. Growing emphasis on allergy preparedness in schools, healthcare systems, and public health programs is indirectly fueling demand for preventive therapies and emergency medications. Furthermore, the chronic nature of peanut allergy necessitates continuous clinical monitoring and follow-up care, increasing outpatient visits, pharmacy interactions, and long-term therapeutic use. The market is also expected to benefit from pipeline innovations such as non-invasive therapies including epicutaneous immunotherapy (EPIT) patches like Viaskin Peanut Patch.

Growing preference for disease-modifying immunotherapies

The peanut allergy treatment landscape is evolving from symptom management toward therapies designed to alter the immune response itself. Historically, peanut allergy management relied heavily on strict allergen avoidance and emergency epinephrine administration during accidental exposure. However, the introduction of oral immunotherapy has significantly transformed treatment strategies.

Modern immunotherapies aim to gradually increase patients’ tolerance thresholds by administering controlled amounts of peanut allergen over time. This approach helps reduce the severity of allergic reactions from accidental exposure while improving patient confidence and overall quality of life. The reduced psychological burden and greater social flexibility offered by these therapies are encouraging broader adoption among patients and caregivers.

Clinical acceptance of immunotherapies continues to grow due to the development of standardized treatment protocols, improved safety monitoring practices, and rising physician familiarity with allergy desensitization programs. Pharmaceutical companies are also increasing investments in allergy-focused biologics and immunotherapy platforms, resulting in expanded clinical trials and innovations in treatment delivery systems such as patches, oral mucosal therapies, and injectable biologics. This ongoing transition toward proactive disease modification is broadening the market potential and reshaping treatment expectations.

Download Sample PDF Copy: https://meditechinsights.com/peanut-allergy-treatment-market/request-sample/

Drug Type Segment Outlook

Based on drug type, the peanut allergy treatment market is segmented into antihistamines, epinephrine, immunotherapies, and other therapies. Epinephrine currently represents the largest market segment owing to its critical role as the primary emergency treatment for severe allergic reactions and anaphylaxis. Its rapid therapeutic action and widespread clinical use continue to support strong market demand.

Antihistamines also maintain a notable market presence as supportive therapies used to manage mild allergy symptoms such as itching, skin irritation, and nasal discomfort. However, immunotherapies are emerging as the fastest-growing segment due to their ability to address the underlying allergic response rather than simply managing symptoms. Increased regulatory approvals, growing physician acceptance, and expanding availability of standardized treatment protocols are accelerating the adoption of immunotherapy-based solutions worldwide.

Regional Outlook: North America dominates the peanut allergy treatment market

North America accounts for a major share of the global peanut allergy treatment market, supported by high allergy prevalence rates, advanced healthcare infrastructure, strong awareness levels, and early adoption of immunotherapy products. The region also benefits from substantial investments in research and development, active clinical trial programs, and favorable regulatory support for innovative therapies, reinforcing its leadership position.

Europe represents the second-largest regional market, driven by increasing patient awareness and well-established allergy management frameworks. However, the pace of adoption for newer therapies differs across European countries depending on reimbursement structures and healthcare accessibility.

Meanwhile, the Asia-Pacific region is expected to witness the fastest growth during the forecast period. Rapid urbanization, changing dietary habits, and evolving lifestyles are contributing to a rise in food allergy incidence across the region. Despite increasing demand, factors such as limited access to specialized allergy care and cost-related barriers in rural areas continue to restrict wider treatment adoption.

Competitive Landscape Analysis

The global peanut allergy treatment market features a mix of established pharmaceutical companies and emerging biotechnology firms focused on developing innovative allergy therapies. Key players operating in the market include DBV Technologies, Sanofi S.A., ALK-Abelló A/S, Prota Therapeutics, Camallergy, Aravax Pty Ltd, Genentech, Viatris Inc., Intrommune Therapeutics, IgGenix, Inc., and Regeneron Pharmaceuticals Inc., among others.

Strategic initiatives shaping the market

Companies operating in the peanut allergy treatment market are actively pursuing strategies such as product launches, regulatory approvals, acquisitions, collaborations, and research partnerships to strengthen their market presence.

For example, in March 2026, GSK completed the acquisition of RAPT Therapeutics to enhance its immunology pipeline, including the development of ozureprubart, a long-acting anti-IgE monoclonal antibody designed for protection against food allergens such as peanuts.

In February 2024, Roche received FDA approval for Xolair (omalizumab), an anti-IgE therapy intended to reduce allergic reactions associated with accidental exposure to multiple food allergens, strengthening the company’s position in food allergy management.

Additionally, in January 2024, Inimmune Corporation and Intrommune Therapeutics entered into a collaboration to develop a rapid and long-acting oral mucosal immunotherapy platform for peanut allergy treatment. The partnership combines oral mucosal immunotherapy technologies with proprietary immunomodulatory approaches aimed at achieving faster and more durable desensitization outcomes.

Browse Report: https://meditechinsights.com/peanut-allergy-treatment-market/

Global Peanut Allergy Treatment Market Segmentation

This report by Medi-Tech Insights provides the size of the global peanut allergy treatment market at the regional and country-level from 2024 to 2031. The report further segments the market by drug type, route of administration, age group, and distribution channel.

Market Size & Forecast (2024-2031), By Drug Type, USD Billion

• Antihistamines
• Epinephrine
• Immunotherapies
• Others

Market Size & Forecast (2024-2031), By Route of Administration, USD Billion

• Oral
• Injectable
• Others

Market Size & Forecast (2024-2031), By Age Group, USD Billion

• Paediatric
• Adult

Market Size & Forecast (2024-2031), By Distribution Channel, USD Billion

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Related Report:

Large Molecule Drug Substance CDMO Market            https://www.pharmiweb.com/press-release/2026-05-15/large-molecule-drug-substance-cdmo-market-emerging-as-a-high-growth-healthcare-investment-space-through-2030

Bioreactors Market   https://www.pharmiweb.com/press-release/2026-05-15/bioreactors-market-to-witness-transformational-growth-opportunities-by-2030

Tricuspid Valve Repair Market         https://www.pharmiweb.com/press-release/2026-05-18/tricuspid-valve-repair-market-will-generate-booming-growth-opportunities-to-2031

Hematology Market  https://www.pharmiweb.com/press-release/2026-05-18/hematology-market-size-share-key-developments-innovations-and-opportunities-through-2031

About Medi-Tech Insights;

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

Contact:

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.comTop